A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles

Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Meador, Lydia R., Kessans, Sarah A., Kilbourne, Jacquelyn, Kibler, Karen V., Pantaleo, Giuseppe, Roderiguez, Mariano Esteban, Blattman, Joseph N., Jacobs, Bertram L., Mor, Tsafrir S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529300/
https://www.ncbi.nlm.nih.gov/pubmed/28458036
http://dx.doi.org/10.1016/j.virol.2017.04.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529300/
https://www.ncbi.nlm.nih.gov/pubmed/28458036
http://dx.doi.org/10.1016/j.virol.2017.04.008

Ejemplares similares